Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a novel approach to addressing neuroinflammation associated with aging. The company highlighted that neuro inflammation is widely recognized as a contributing factor to cognitive decline in age-related neurological conditions. #SlimScan #GrowthStocks #CANSLIM